OBJECTIVES: To assess the short-term compliance with fesoterodine treatment and to identify the reasons for lack of adherence and discontinuation in routine clinical practice.
The secondary aim was to estimate the patient-reported outcomes.
METHODS: This was an observational retrospective, multicenter study conducted in a sample of women with overactive bladder on fesoterodine treatment for at least three months. Adherence to medication was assessed using the Morisky-Green test. Patient-reported outcomes were assessed using the Incontinence Questionnaire Short Form (ICIQ-SF), Overactive Bladder Questionnaire Short Form (OAB-qSF), and Treatment Benefit Scale (TBS).
RESULTS: One hundred and twenty women with a mean age (standard deviation (SD)) of 62.2 (12.0) years with severe OAB (mean (SD) ICIQ-SF score 13.2 (4.0)) were included. 42.1% of the patients were considered compliant with fesoterodine treatment. The main causes for non-compliance/discontinuation stated by the remaining 57.9% of the patients were adverse events (62.2%) and lack of clinical benefits (20.0%). The illness status as well as the patient-perceived bother occasioned by the OAB symptoms and their impact on the quality of life improved significantly after three months on fesoterodine treatment (p< 0.0001). Most of the patients stated that the current state of their urinary problems had greatly improved/ improved.
CONCLUSION: In routine clinical practice, a high percentage of patients were adherent to fesoterodine and perceived the benefit that the treatment provided them three months after starting treatment. However, more than half of the study population failed to comply or discontinued the treatment mainly due to intolerance or lack of efficacy.
Written by:
Simó M, Porta O, Pubill J, Castillo MT, Mora I, Huguet E, Ortega JA, Martínez E. Are you the author?
Departamento de Obstetricia y Ginecología, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Departamento de Obstetricia y Ginecología, Corporació Sanitària Parc Taulí, Barcelona, España; Departamento de Obstetricia y Ginecología, Parc de Salut Mar, Barcelona, España; Departamento de Obstetricia y Ginecología, Hospital d'Igualada, Barcelona, España; Departamento de Obstetricia y Ginecología, Hospital Viladecans, Barcelona, España; PASSIR Dreta, Institut Català de la Salut, Barcelona, España; Departamento de Obstetricia y Ginecología, Parc Sanitari Sant Joan de Déu Sant Boi, Barcelona, España.
Reference: Actas Urol Esp. 2014 Oct 25. pii: S0210-4806(14)00340-4.
doi: 10.1016/j.acuro.2014.05.013
PubMed Abstract
PMID: 25442908
Article in English, Spanish.